Top

Published in:

01-06-2011 | Review

The role of osteocalcin in the endocrine cross-talk between bone remodelling and energy metabolism

Author: P. Ducy

Published in: Diabetologia | Issue 6/2011

Abstract

Bone remodelling, which maintains bone mass constant during adulthood, is an energy-demanding process. This, together with the observation that the adipocyte-derived hormone leptin is a major inhibitor of bone remodelling, led to the hypothesis that bone cells regulate energy metabolism through an endocrine mechanism. Studies to test this hypothesis identified osteocalcin, a hormone secreted by osteoblasts, as a positive regulator of insulin secretion, insulin resistance and energy expenditure. Remarkably, insulin signalling in osteoblasts is a positive regulator of osteocalcin production and activation via its ability to indirectly enhance bone resorption by osteoclasts. In contrast, leptin is a potent inhibitor of osteocalcin function through its effect on the sympathetic tone. Hence, osteocalcin is part of a complex signalling network between bone and the organs more classically associated with the regulation of energy homeostasis, such as the pancreas and adipose tissue. This review summarises the molecular and cellular bases of the present knowledge on osteocalcin biology and discusses the potential relevance of osteocalcin to human metabolism and pathology.

Lee NK, Sowa H, Hinoi E et al (2007) Endocrine regulation of energy metabolism by the skeleton. Cell 130:456–469PubMedCrossRef

Ferron M, Hinoi E, Karsenty G, Ducy P (2008) Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci USA 105:5266–5270PubMedCrossRef

Hinoi E, Gao N, Jung DY et al (2008) The sympathetic tone mediates leptin’s inhibition of insulin secretion by modulating osteocalcin bioactivity. J Cell Biol 183:1235–1242PubMedCrossRef

Yoshizawa T, Hinoi E, Jung DY et al (2009) The transcription factor ATF4 regulates glucose metabolism in mice through its expression in osteoblasts. J Clin Invest 119:2807–2817PubMedCrossRef

Hauschka PV, Lian JB, Cole DE, Gundberg CM (1989) Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev 69:990–1047PubMed

Price PA (1989) Gla-containing proteins of bone. Connect Tissue Res 21:51–57, discussion 57–60PubMedCrossRef

Ferron M, Wei J, Yoshizawa T et al (2010) Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell 142:296–308PubMedCrossRef

Ferron M, Wei J, Yoshizawa T, Ducy P, Karsenty G (2010) An ELISA-based method to quantify osteocalcin carboxylation in mice. Biochem Biophys Res Commun 397:691–696PubMedCrossRef

Dacquin R, Mee PJ, Kawaguchi J et al (2004) Knock-in of nuclear localised β-galactosidase reveals that the tyrosine phosphatase Ptprv is specifically expressed in cells of the bone collar. Dev Dyn 229:826–834PubMedCrossRef

10.

Teitelbaum SL, Ross FP (2003) Genetic regulation of osteoclast development and function. Nat Rev Genet 4:638–649PubMedCrossRef

11.

Price PA, Williamson MK, Epstein DJ (1981) Specific tritium incorporation into γ-carboxyglutamic acid in proteins. The pH dependence of γ-proton exchange. J Biol Chem 256:1172–1176PubMed

12.

Price PA, Poser JW, Raman N (1976) Primary structure of the γ-carboxyglutamic acid-containing protein from bovine bone. Proc Natl Acad Sci USA 73:3374–3375PubMedCrossRef

13.

Gundberg CM, Weinstein RS (1986) Multiple immunoreactive forms of osteocalcin in uremic serum. J Clin Invest 77:1762–1767PubMedCrossRef

14.

Ivaska KK, Hentunen TA, Vaaraniemi J, Ylipahkala H, Pettersson K, Vaananen HK (2004) Release of intact and fragmented osteocalcin molecules from bone matrix during bone resorption in vitro. J Biol Chem 279:18361–18369PubMedCrossRef

15.

Engelke JA, Hale JE, Suttie JW, Price PA (1991) Vitamin K-dependent carboxylase: utilization of decarboxylated bone Gla protein and matrix Gla protein as substrates. Biochim Biophys Acta 1078:31–34PubMedCrossRef

16.

Silver IA, Murrills RJ, Etherington DJ (1988) Microelectrode studies on the acid microenvironment beneath adherent macrophages and osteoclasts. Exp Cell Res 175:266–276PubMedCrossRef

17.

Scimeca JC, Franchi A, Trojani C et al (2000) The gene encoding the mouse homologue of the human osteoclast-specific 116-kDa V-ATPase subunit bears a deletion in osteosclerotic (oc/oc) mutants. Bone 26:207–213PubMedCrossRef

18.

Fisher JE, Rogers MJ, Halasy JM et al (1999) Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 96:133–138PubMedCrossRef

19.

Fulzele K, Riddle RC, DiGirolamo DJ et al (2010) Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell 142:309–319PubMedCrossRef

20.

Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G (1997) Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 89:747–754PubMedCrossRef

21.

Puigserver P, Rhee J, Donovan J et al (2003) Insulin-regulated hepatic gluconeogenesis through FOXO1–PGC-1α interaction. Nature 423:550–555PubMedCrossRef

22.

Wei J, Ducy P (2010) Co-dependence of bone and energy metabolisms. Arch Biochem Biophys 503:35–40PubMedCrossRef

23.

Yadav VK, Oury F, Suda N et al (2009) A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell 138:976–989PubMedCrossRef

24.

Takeda S, Elefteriou F, Levasseur R et al (2002) Leptin regulates bone formation via the sympathetic nervous system. Cell 111:305–317PubMedCrossRef

25.

Elefteriou F, Ahn JD, Takeda S et al (2005) Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 434:514–520PubMedCrossRef

26.

Kindblom JM, Ohlsson C, Ljunggren O et al (2009) Plasma osteocalcin is inversely related to fat mass and plasma glucose in elderly Swedish men. J Bone Miner Res 24:785–791PubMedCrossRef

27.

Lee YJ, Lee H, Jee SH et al (2010) Serum osteocalcin is inversely associated with adipocyte-specific fatty acid-binding protein in the Korean metabolic syndrome research initiatives. Diabetes Care 33:e90PubMedCrossRef

28.

Pittas AG, Harris SS, Eliades M, Stark P, Dawson-Hughes B (2009) Association between serum osteocalcin and markers of metabolic phenotype. J Clin Endocrinol Metab 94:827–832PubMedCrossRef

29.

Saleem U, Mosley TH Jr, Kullo IJ (2010) Serum osteocalcin is associated with measures of insulin resistance, adipokine levels, and the presence of metabolic syndrome. Arterioscler Thromb Vasc Biol 30:1474–1478PubMedCrossRef

30.

Hwang YC, Jeong IK, Ahn KJ, Chung HY (2009) The uncarboxylated form of osteocalcin is associated with improved glucose tolerance and enhanced beta-cell function in middle-aged male subjects. Diabetes Metab Res Rev 25:768–772PubMedCrossRef

31.

Kanazawa I, Yamaguchi T, Yamamoto M et al (2009) Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. J Clin Endocrinol Metab 94:45–49PubMedCrossRef

32.

Im JA, Yu BP, Jeon JY, Kim SH (2008) Relationship between osteocalcin and glucose metabolism in postmenopausal women. Clin Chim Acta 396:66–69PubMedCrossRef

33.

Bao YQ, Zhou M, Zhou J et al (2011) Relationship between serum osteocalcin and glycemic variability in type 2 diabetes. Clin Exp Pharmacol Physiol 38:50–54PubMedCrossRef

34.

Zhou M, Ma X, Li H et al (2009) Serum osteocalcin concentrations in relation to glucose and lipid metabolism in Chinese individuals. Eur J Endocrinol 161:723–729PubMedCrossRef

35.

Winhofer Y, Handisurya A, Tura A et al (2010) Osteocalcin is related to enhanced insulin secretion in gestational diabetes mellitus. Diabetes Care 33:139–143PubMedCrossRef

36.

Goliasch G, Blessberger H, Azar D et al (2010) Markers of bone metabolism in premature myocardial infarction (≤40 years of age). Bone 48:622–626PubMedCrossRef

37.

Reinehr T, Roth CL (2010) A new link between skeleton, obesity and insulin resistance: relationships between osteocalcin, leptin and insulin resistance in obese children before and after weight loss. Int J Obes (Lond) 34:852–858CrossRef

38.

Yeap BB, Chubb SA, Flicker L et al (2010) Reduced serum total osteocalcin is associated with metabolic syndrome in older men via waist circumference, hyperglycemia, and triglyceride levels. Eur J Endocrinol 163:265–272PubMedCrossRef

39.

Das SK, Sharma NK, Elbein SC (2010) Analysis of osteocalcin as a candidate gene for type 2 diabetes (T2D) and intermediate traits in Caucasians and African Americans. Dis Markers 28:281–286PubMed

40.

Bonnefond A, Froguel P, Vaxillaire M (2010) The emerging genetics of type 2 diabetes. Trends Mol Med 16:407–416PubMedCrossRef

41.

Ramos E, Chen G, Shriner D et al (2010) Replication of genome-wide association studies (GWAS) loci for fasting plasma glucose in African-Americans. Diabetologia 54:783–788PubMedCrossRef

42.

Cairns JR, Price PA (1994) Direct demonstration that the vitamin K-dependent bone Gla protein is incompletely gamma-carboxylated in humans. J Bone Miner Res 9:1989–1997PubMedCrossRef

43.

Vergnaud P, Garnero P, Meunier PJ, Breart G, Kamihagi K, Delmas PD (1997) Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS Study. J Clin Endocrinol Metab 82:719–724PubMedCrossRef

44.

Nimptsch K, Hailer S, Rohrmann S, Gedrich K, Wolfram G, Linseisen J (2007) Determinants and correlates of serum undercarboxylated osteocalcin. Ann Nutr Metab 51:563–570PubMedCrossRef

45.

Aonuma H, Miyakoshi N, Hongo M, Kasukawa Y, Shimada Y (2009) Low serum levels of undercarboxylated osteocalcin in postmenopausal osteoporotic women receiving an inhibitor of bone resorption. Tohoku J Exp Med 218:201–205PubMedCrossRef

46.

Lee AJ, Hodges S, Eastell R (2000) Measurement of osteocalcin. Ann Clin Biochem 37:432–446PubMedCrossRef

47.

Prats-Puig A, Mas-Parareda M, Riera-Perez E et al (2010) Carboxylation of osteocalcin affects its association with metabolic parameters in healthy children. Diabetes Care 33:661–663PubMedCrossRef

48.

Pollock NK, Bernard PJ, Wenger K et al (2010) Lower bone mass in prepubertal overweight children with prediabetes. J Bone Miner Res 25:2484–2493CrossRef

49.

Kanazawa I, Yamaguchi T, Yamauchi M et al (2010) Serum undercarboxylated osteocalcin was inversely associated with plasma glucose level and fat mass in type 2 diabetes mellitus. Osteoporos Int 22:187–194PubMedCrossRef

50.

Fernandez-Real JM, Izquierdo M, Ortega F et al (2009) The relationship of serum osteocalcin concentration to insulin secretion, sensitivity, and disposal with hypocaloric diet and resistance training. J Clin Endocrinol Metab 94:237–245PubMedCrossRef

51.

Levinger I, Zebaze R, Jerums G, Hare DL, Selig S, Seeman E (2011) The effect of acute exercise on undercarboxylated osteocalcin in obese men. Osteoporos Int 22:1621–1626PubMedCrossRef

Title: The role of osteocalcin in the endocrine cross-talk between bone remodelling and energy metabolism
Author: P. Ducy
Publication date: 01-06-2011
Publisher: Springer-Verlag
Published in: Diabetologia / Issue 6/2011
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-011-2155-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2011

The four-variable modification of diet in renal disease formula underestimates glomerular filtration rate in obese type 2 diabetic individuals with chronic kidney disease

Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin–Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study

Genetic variants near the IRS1 gene, physical activity and type 2 diabetes in US men and women

Advanced glycation end-products induce basement membrane hypertrophy in endoneurial microvessels and disrupt the blood–nerve barrier by stimulating the release of TGF-β and vascular endothelial growth factor (VEGF) by pericytes

No effect by the common gene variant rs10830963 of the melatonin receptor 1B on the association between sleep disturbances and type 2 diabetes: results from the Nord-Trøndelag Health Study

Natural history and physiological determinants of changes in glucose tolerance in a non-diabetic population: the RISC Study

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials